Sage Therapeutics Financial Summary for 2024
Sage Therapeutics, Inc. (Nasdaq: SAGE) is delighted to share its financial performance and pipeline advancements for the fourth quarter and full year results concluded at the end of 2024.
CEO Barry Greene expressed pride in assisting numerous women grappling with postpartum depression during 2024, highlighting ZURZUVAE's essential role in mental health care. The focus for 2025 is to broaden access to ZURZUVAE, enhance research and development (R&D) efforts, and ensure sustained growth and value for stakeholders.
Portfolio Updates in the Fourth Quarter of 2024
ZURZUVAE Achievements
Sage is committed to positioning ZURZUVAE as the leading treatment option for postpartum depression (PPD). The company has outlined a commercialization strategy involving expanded sales teams and digital marketing initiatives. These efforts aim to drive market growth in PPD while increasing awareness about the disease to facilitate better screening and diagnosis.
As a testament to the success of these strategies, nearly 2,500 prescriptions were processed in the fourth quarter alone, marking a 21% increase from the previous quarter. In total, over 6,600 prescriptions were filled during the entire year of 2024.
Collaboration Revenues from ZURZUVAE
The fourth quarter generated $11.4 million in collaboration revenue resulting from ZURZUVAE shipments. This revenue represents a substantial uplift from previous periods, reflecting strong market acceptance. For the full year, collaboration revenue reached $36.1 million, marking a significant achievement for Sage.
Insurance and Prescriber Coverage
More than 95% of commercial and Medicaid beneficiaries have access to ZURZUVAE, with a majority experiencing simplified approval processes. All major pharmacy benefit managers (PBMs) have also established favorable policies for ZURZUVAE, ensuring wide availability.
During Q4 2024, obstetricians and gynecologists (OBGYNs) wrote nearly 80% of prescriptions for ZURZUVAE, with a remarkable 60% of healthcare providers reporting repeat prescriptions. Furthermore, over 70% of patients began treatment with ZURZUVAE as their primary option for PPD.
Emerging Clinical Developments
SAGE-319
SAGE-319, a novel GABAA receptor modulator, is currently being evaluated for its potential to alleviate behavioral symptoms in certain neurodevelopmental conditions. The company anticipates data from an ongoing Phase 1 study by 2025, which will guide future steps.
Research and Development Initiatives
Alongside SAGE-319, Sage is actively pursuing innovative therapies within its NMDA receptor negative allosteric modulator (NAM) platform to address neurodevelopmental disorders, utilizing compounds such as SAGE-817 and SAGE-039.
Financial Overview
Summary of Q4 2024 Financial Results
As of December 31, 2024, Sage reported a cash, cash equivalents, and marketable securities balance of $504 million, a decrease from $569 million at the close of Q3 2024. Revenue from collaboration concerning ZURZUVAE was recorded at $11.4 million for Q4 2024, compared to just $0.8 million for the same quarter in 2023.
Expenses in relation to research and development amounted to $37 million for Q4 2024, significantly reduced from $64.3 million the previous year. This reduction can be attributed to cost-saving measures and adjustments in project prioritization.
Guidance for Future Financial Performance
Sage has projected that its existing funds, including cash and collaboration revenue, will adequately support operations through mid-2027. Even though investment in ZURZUVAE commercialization is expected to rise in 2025, an overall decrease in operational costs is also anticipated.
The company has scheduled a conference call to discuss its Q4 2024 financial results and broader corporate updates, which will be available through their investor page.
About Sage Therapeutics
Sage Therapeutics (Nasdaq: SAGE) is at the forefront of biopharmaceutical innovation, focused on developing transformative treatments for brain health. The company is known for pioneering solutions in mental health, having produced the only two FDA-approved therapies for postpartum depression. Established in 2010, Sage is on a mission to enhance life quality through its groundbreaking research and offerings.
Frequently Asked Questions
What is ZURZUVAE?
ZURZUVAE is a medication specifically designed for treating postpartum depression, acting as a GABAA receptor modulator.
How did Sage Therapeutics perform in 2024?
Sage Therapeutics reported significant revenue growth, driven primarily by ZURZUVAE's market penetration.
What is Sage's future outlook?
The company aims to maintain growth through continued investment in research and increased commercialization for ZURZUVAE in future years.
How much collaboration revenue did Sage generate?
Sage generated $11.4 million in collaboration revenue from ZURZUVAE in Q4 2024, with total revenue for the year reaching $36.1 million.
What other products is Sage developing?
Sage is exploring advanced therapies, including SAGE-319, focusing on neurodevelopmental disorders using its NAM platform.
